印度新增34.3万宗确诊 政府顾问料下半年可获20亿剂疫苗
印度疫情持续严峻,据印度卫生部数据,过去24小时新增34.31万宗新冠肺炎确诊病例,累计确诊2,405万宗;新增4,000宗死亡病例,累计死亡26.23万宗,连续三日单日录4,000宗或以上死亡病例。
印度政府卫生顾问V K Paul周四(13日)称,料印度今年8月至12月间可获得逾20亿剂新冠疫苗,包括由印度血清研究所(SII)生产的7.5亿剂阿斯利康(AZN.US)疫苗,以及5.5亿剂本国生科企业Bharat Biotech研发的Covaxin疫苗。
印度人口最多邦(达2.4亿人)北方邦将斥资最多13.6亿美元(约1,000亿卢比)购买新冠疫疫苗,本周已与辉瑞(PFE.US)及俄罗斯Sputnik V生产商的当地夥伴Dr. Reddy’s Laboratories接洽。该邦发言人亦称,已与获授生产阿斯利康及Novavax疫苗的SII、印度生科企业Bharat Biotech及Cadila Healthcare作采购前接洽,仍为未来数月全球招标采购4,000万剂新冠疫苗的一部分。发言人确认强生(JNJ.US)已透过电邮表达参与意向。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.